{"id":381851,"date":"2026-04-08T18:50:11","date_gmt":"2026-04-08T18:50:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/381851\/"},"modified":"2026-04-08T18:50:11","modified_gmt":"2026-04-08T18:50:11","slug":"indias-generic-semaglutide-surge-opinion","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/381851\/","title":{"rendered":"India\u2019s generic semaglutide surge | Opinion"},"content":{"rendered":"

Generic drugmakers in India had 20 March 2026 marked in their calendars for quite a while. That\u2019s the date that Indian patents protecting Novo Nordisk\u2019s semaglutide (Ozempic\/Wegovy) expired. Dozens of generic versions of the drugs are now expected to enter the market, at significantly lower prices than Novo\u2019s.<\/p>\n

Semaglutide kick-started a\u00a0transformation in treating diabetes and obesity<\/a>. Along with Eli Lilly\u2019s related tirzepatide (Mounjaro\/Zepbound), these new drugs have stormed towards the top of drug sales lists. They have also stimulated a pipeline of follow-up injectable and\u00a0oral drugs<\/a>, as other companies attempt to enter a lucrative market, while Novo and Lilly seek to reinforce their positions as market leaders.<\/p>\n

\"An<\/p>\n

Three factors have combined in India\u2019s rapid introduction of generic semaglutide. First, India\u2019s patent laws make it difficult to extend patent protection<\/a> on medicines by tweaking processes or formulations. That means Novo\u2019s patents are expiring earlier in India than in many other countries. That said, owing to a remarkable oversight, Novo\u2019s\u00a0Canadian patent lapsed<\/a>\u00a0after the company failed to pay its maintenance fees. But while generic versions could have been introduced in Canada earlier this year, so far, they haven\u2019t appeared.<\/p>\n

Secondly, India is home to many of the world\u2019s most successful generic drug manufacturers. Their combined infrastructure and expertise in developing cost-effective manufacturing processes is enormous. Finally, demand for these medications in India is increasing rapidly, owing to growing numbers of people in India with diabetes and obesity \u2013 many of whom cannot afford Novo\u2019s prices. That makes for an enormous opportunity for generics.<\/p>\n

The bonanza of generic semaglutide medicines in India will likely be accompanied by intensive marketing efforts as the various manufacturers compete for their share. But amidst that clamour there is a significant risk of some producers taking advantage of the proliferation to sell unauthorised versions of the drugs, or using improper marketing practices to gain an unfair \u2013 and potentially unsafe for patients \u2013 advantage.<\/p>\n

Anticipating such potential problems, India\u2019s drug regulator has\u00a0increased its regulatory surveillance and enforcement<\/a>\u00a0around the supply chain for GLP-1 weight loss drugs. In the weeks leading up to the release of authorised generics, the regulator increased inspections at online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics.<\/p>\n

The rest of the world will be watching closely as the landscape unfolds in India, both in terms of price competition and influence on prescriptions of semaglutide medicines compared to Lilly\u2019s tirzepatide. In many countries\u00a0tirzepatide has been overtaking semaglutide<\/a>\u00a0on the back of trial results suggesting marginally greater effectiveness. The most successful Indian manufacturers will also have an eye on rapid expansion into worldwide markets as patents expire in China, Brazil, Turkey and South Africa<\/a> later this year. Novo\u2019s EU and UK patent protection will last into 2031, and in the US until at least 2032.<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Generic drugmakers in India had 20 March 2026 marked in their calendars for quite a while. That\u2019s the…\n","protected":false},"author":2,"featured_media":381852,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[163,85,46,482],"class_list":{"0":"post-381851","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-il","10":"tag-israel","11":"tag-medication"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/381851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=381851"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/381851\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/381852"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=381851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=381851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=381851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}